Abstract
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig' s disease in the
US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a
progressive neuromuscular disease characterised by the progressive
degeneration of motor nerve cell in the brain (upper motor neurons) and spinal
cord (lower motor). To date there is no cure for ALS. Present day medical
management of the disease through the combinatorial use of medications and
advancements in state-of-art technological devices for nutrition and
breathing, have markedly increased the survival rate of ALS sufferers.
An article in SpokesmanReview states their may be a link between statins and
ALS, with suggestions that Lipitor has triggered it in certain cases. The
article sites the WHO as pointing out that high numbers have developed Lou
Gehrig disease while on statins and advises doctors to discontinue therapy if
patients develop ' serious neuromuscular disease such as ALS like symptoms' .
Could Lipitor (still the biggest selling drug) actually cause ALS while the
company itself thinks it will aid in the treatment of MS?
The report examines key ALS/ Lou Gehrig markets such as:
- US
- Japan
- Germany
- France
- Italy
- Spain
- UK
Sanofi-Aventis' Rilutek (riluzole) is the only prescription drug currently
approved for the treatment of ALS. Rilutek generated global revenue of over
$153 million in 2006. Visiongain reveals that, Rilutek' s market value will
continue to expand with, global revenues anticipated to exceed, $129 million
2007 in the seven major markets across the globe. What will it be in 2012?
This report tells you.
Visiongain' s ALS Market Analysis & Forecasts, delves into Rilutek' s monopoly
over the market in recent years, it present market share and trends envisaged
in the medium future. This current report presents a three hundred and sixty
degree examination of how present changes in Governmental Pharmaceutical
Policies will impact on Rilutek as the main treatment for ALS in the seven
major markets. Plus we examine how current and new drug treatments can take
hold of the market, plus which companies will succeed in each market.
The report provides in-depth market analysis upon these areas, and extensively
identifies the challenges faced by new market entrants, and what exciting
market opportunities exist in this therapeutic area.
Why You Must Buy This Report? This report features tables, graphs and charts,
news, insights, the past and present developments in ALS research. This
report, will provide you with the complete understanding of the market
indications for ALS, the institutions heralding ALS research, companies on the
outlook to join in decoding, such matters as- directions to meeting primary
unmet needs in ALS. When you buy this report, you have also bought, why big
players in the biopharmaceutical business are filling their portfolios niche
medical devices and diagnostics technologies products through major M&A.
With unmet medical needs this is this market set to grow with an ageing
population and by how much? This report will tell you. Brought together in one
easy to read, easily digested format, this report will keep you fully informed
and up-to-date on the global ALS pharmaceutical market.
Why You Must Buy This Report: This report features tables, graphs and charts,
news, insights, the past and present developments in ALS research. This
report, will provide you with the complete understanding of the market
indications for ALS, the institutions heralding ALS research, companies on the
outlook to join in decoding, such matters as- directions to meeting primary
unmet needs in ALS. When you buy this report, you have also bought, why big
players in the biopharmaceutical business are filling their portfolios niche
medical devices and diagnostics technologies products through major M&A.
Key questions that this report answers are:
- What research over the past 20 years has failed? And why
- What R&D opportunities exist for ' new comers' ?
- Which current or future therapies will drive the ALS market?
- The key companies involved in the market and their analysis?
- What companies are joining in ALS research?
- What treatment besides Rilutek, can improve ALS survival rate?
- Which of the major markets has the highest prevalence?
- What is the present state of the disease awareness?
- Who are market leaders in medical devices M&A activities?
- Which emerging markets are forcing big pharma into M&A deals?
Unique benefits to you when you order this report:
- You can access your report whichever country you are in without using
harddrive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
View Cart
